PARIS (Reuters) – French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple sclerosis in early 2024.
(Reporting by Sudip Kar-Gupta; Editing by Shri Navaratnam)
Keyword: Text NEWS to 39327*
Details: Breaking News Alerts
Messages: expect up to 1 per week
Keyword: Text WEATHER to 39327*
Details: Daily Weather Forecast
Messages: expect up to 7 per week
Sponsor: King’s Campers
Keyword: Text TRAFFIC to 39327*
Details: Traffic and road alerts
Messages: expect up to 5 per week
*Message & data rates may apply. Text STOP to 39327 to quit. Text HELP for help or visit www.vibes.com/help/ for support. No purchase necessary. Marketing text messages generated by an automated dialer will be delivered to the phone number you provide at opt-in
